# Focal Pancreatic Parenchymal Atrophy in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas

**Authors:** Hidehito Sumiya, Shinsuke Koshita, Yoshihide Kanno, Takahisa Ogawa, Hiroaki Kusunose, Toshitaka Sakai, Masaya Oikawa, Takashi Sawai, Yutaka Noda, Kei Ito

PMC · DOI: 10.7759/cureus.98506 · 2025-12-05

## TL;DR

The study found that focal pancreatic atrophy is present in about 20% of pancreatic tumors called MD-IPMNs, and these tumors may represent an early stage of the disease.

## Contribution

This study is the first to clarify the relationship between focal pancreatic atrophy and MD-IPMNs, suggesting a biologically distinct subset.

## Key findings

- Focal pancreatic parenchymal atrophy (FPPA) was observed in 21% of MD-IPMN patients.
- MD-IPMNs in FPPA patients had a significantly smaller main pancreatic duct diameter compared to those with upstream atrophy.
- In 75% of FPPA cases, the tumor was histologically contained within the atrophic area.

## Abstract

Introduction

Although upstream pancreatic atrophy (UPA) is a characteristic finding in main duct intraductal papillary mucinous neoplasms (MD-IPMNs) of the pancreas, the relationship between MD-IPMNs and focal pancreatic parenchymal atrophy (FPPA), which is an indicator of early-stage pancreatic ductal adenocarcinoma, remains unclear. Thus, this study aimed to investigate the relationship.

Methods

From the 49 patients diagnosed with MD-IPMNs using the resected specimens from June 2003 to December 2023, 19 patients were selected to clarify the clinical characteristics of FPPA for MD-IPMN patients. The primary outcome measure was the frequency of FPPA/UPA. Secondary outcome measures were (1) the locational relationship between MD-IPMN and FPPA and (2) the clinicopathological differences between those atrophic types.

Results

FPPA and UPA were observed in 4 (21%) and 12 (63%) patients, respectively. When the clinicopathological factors of FPPA and UPA patients were compared, only the diameter of the main pancreatic duct (MPD) significantly differed (median MPD diameter: 6 mm vs. 11 mm, p = 0.017). Of the four patients with FPPA, the histological extent of the MD-IPMN lesion was within that of FPPA in three patients (75%) and was concordant with that of FPPA only in one patient (25%).

Conclusions

FPPAs were detected in approximately 20% of resected MD-IPMNs, and 75% of those MD-IPMNs were histologically included in the area of the FPPAs. Since the MPD diameter was significantly smaller for MD-IPMNs with FPPAs than those with UPAs, MD-IPMNs with FPPAs may be biologically related to the mild dilation of the MPD, such as lesions at an early stage or less mucin secretion.

## Linked entities

- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)

## Full-text entities

- **Genes:** mucin [NCBI Gene 100508689]
- **Diseases:** atrophic types (MESH:D020966), FPPA (MESH:D010195), pancreatic ductal adenocarcinoma (MESH:D021441), Duct Intraductal Papillary Mucinous Neoplasms (MESH:D000077779)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12765621/full.md

---
Source: https://tomesphere.com/paper/PMC12765621